Kush M Parmar is a managing partner at 5AM Ventures. He serves as a director on the boards of Akouos, Arvinas, Entrada, Homology, Rally Bio and Vor Biopharma. He previously served as Acting Vice President of Strategy and Corporate Development at Novira and served as board member or observer for Achaogen, Audentes, Envoy and scPharmaceuticals. He serves on the advisory boards of Penn Medicine, Princeton University’s Department of Molecular Biology and the Grace Science Foundation. He is a fellow of the Society of Kauffman Fellows. Prior to 5AM, Parmar was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at Massachusetts General and Brigham and Women’s Hospitals. At Princeton University, Parmar worked on developmental genetics with Eric Wieschaus. He holds an A.B. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University and an M.D. from Harvard Medical School.